Opaleye Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Opaleye Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-110,000	Closed	-$622K	–	50
2016 Q4	$622K	Sell	110,000 -65,000	-37%	-$647K	0.37%	38
2016 Q3	$2.59M	Sell	175,000 -20,000	-10%	-$230K	1.35%	26
2016 Q2	$1.75M	Hold	195,000	–	–	1.17%	33
2016 Q1	$1.8M	Sell	195,000 -15,000	-7%	-$126K	1.13%	33
2015 Q4	$2.65M	Sell	210,000 -35,275	-14%	-$490K	1.11%	36
2015 Q3	$3.2M	Sell	245,275 -4,725	-2%	-$86.8K	1.57%	27
2015 Q2	$5.46M	Sell	250,000 -10,000	-4%	-$228K	2.17%	20
2015 Q1	$5.26M	Sell	260,000 -73,333	-22%	-$1.08M	2.44%	20
2014 Q4	$3M	Buy	+333,333	New	+$2.6M	1.52%	25

Other funds holding TRIL

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Opaleye Management's TRIL Position: Q1 2017 in Review

Opaleye Management sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2017, closing a stake of 110,000 shares — an estimated $622K sold.

Opaleye Management first reported a position in TRIL in Q4 2014 and held it in 9 quarters. The position peaked at $5.46M in Q2 2015. 22 funds tracked by Wall St. Rank hold TRIL as of Q1 2017.

Opaleye Management reported no remaining Trillium Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
Opaleye Management sold 110,000 Trillium Therapeutics Inc. shares in Q1 2017, an estimated $622K.
Opaleye Management first reported a position in Trillium Therapeutics Inc. in Q4 2014 and held it in 9 quarters.
Opaleye Management's Trillium Therapeutics Inc. position peaked at $5.46M in Q2 2015.
22 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2017.

Based on Opaleye Management's 13F filing for Q1 2017, filed 15 May 2017.